{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:45:24Z","timestamp":1791906324360,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["18411965600"],"award-info":[{"award-number":["18411965600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Key Clinical Specialty","award":["shslczdzk00801"],"award-info":[{"award-number":["shslczdzk00801"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00405-023-08430-x","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T08:02:07Z","timestamp":1704441727000},"page":"1865-1875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic bevacizumab for treatment of recurrent respiratory papillomatosis"],"prefix":"10.1007","volume":"281","author":[{"given":"Xiaoyun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufa","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0185-5997","authenticated-orcid":false,"given":"Chunsheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"issue":"4","key":"8430_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1177\/0194599820931817","volume":"163","author":"RC Hoesli","year":"2020","unstructured":"Hoesli RC, Wingo ML, Richardson BE, Bastian RW (2020) Identification of 11 different HPV subtypes in adult patients with recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 163(4):785\u2013790. https:\/\/doi.org\/10.1177\/0194599820931817","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"8430_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/lio2.545","volume":"6","author":"JJ Benedict","year":"2021","unstructured":"Benedict JJ, Derkay CS (2021) Recurrent respiratory papillomatosis: A 2020 perspective. Laryngosc Investig Otolaryngol 6(2):340\u2013345. https:\/\/doi.org\/10.1002\/lio2.545","journal-title":"Laryngosc Investig Otolaryngol"},{"issue":"14","key":"8430_CR3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/14656566.2021.1935870","volume":"22","author":"AJ Donne","year":"2021","unstructured":"Donne AJ, Kinshuck A (2021) Pharmacotherapy for recurrent respiratory papillomatosis (RRP): a treatment update. Expert Opin Pharmacother 22(14):1901\u20131908. https:\/\/doi.org\/10.1080\/14656566.2021.1935870","journal-title":"Expert Opin Pharmacother"},{"key":"8430_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/000348940911800901","volume":"201","author":"SM Zeitels","year":"2009","unstructured":"Zeitels SM, Lopez-Guerra G, Burns JA, Lutch M, Friedman AM, Hillman RE (2009) Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol Suppl 201:1\u201313. https:\/\/doi.org\/10.1177\/000348940911800901","journal-title":"Ann Otol Rhinol Laryngol Suppl"},{"issue":"7","key":"8430_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1055\/s-0029-1214714","volume":"63","author":"S Nagel","year":"2009","unstructured":"Nagel S, Busch C, Blankenburg T, Sch\u00fctte W (2009) Behandlung der respiratorischen Papillomatose-Kasuistik zur systemischen Therapie mit Bevacizumab [Treatment of respiratory papillomatosis\u2014a case report on systemic treatment with bevacizumab]. Pneumologie 63(7):387\u2013389. https:\/\/doi.org\/10.1055\/s-0029-1214714","journal-title":"Pneumologie"},{"issue":"5","key":"8430_CR6","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3892\/ol.2014.2486","volume":"8","author":"M Mohr","year":"2014","unstructured":"Mohr M, Schliemann C, Biermann C et al (2014) Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett 8(5):1912\u20131918. https:\/\/doi.org\/10.3892\/ol.2014.2486","journal-title":"Oncol Lett"},{"issue":"6","key":"8430_CR7","doi-asserted-by":"publisher","first-page":"E1941","DOI":"10.1002\/lary.29343","volume":"131","author":"DR Sidell","year":"2021","unstructured":"Sidell DR, Balakrishnan K, Best SR et al (2021) Systemic bevacizumab for treatment of respiratory papillomatosis: international consensus statement. Laryngoscope 131(6):E1941\u2013E1949. https:\/\/doi.org\/10.1002\/lary.29343","journal-title":"Laryngoscope"},{"key":"8430_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1044\/1058-0360.0603.66","volume":"6","author":"BH Jacobson","year":"1997","unstructured":"Jacobson BH, Johnson A, Grywalsky C et al (1997) The voice handicap index (VHI): development and validation. Am J Speech Lang Pathol 6:66\u201370. https:\/\/doi.org\/10.1044\/1058-0360.0603.66","journal-title":"Am J Speech Lang Pathol"},{"issue":"1","key":"8430_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijporl.2006.09.004","volume":"71","author":"KB Zur","year":"2007","unstructured":"Zur KB, Cotton S, Kelchner L, Baker S, Weinrich B, Lee L (2007) Pediatric voice handicap index (pVHI): a new tool for evaluating pediatric dysphonia. Int J Pediatr Otorhinolaryngol 71(1):77\u201382. https:\/\/doi.org\/10.1016\/j.ijporl.2006.09.004","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"1","key":"8430_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00005537-200101000-00011","volume":"111","author":"CS Derkay","year":"2001","unstructured":"Derkay CS (2001) Recurrent respiratory papillomatosis. Laryngoscope 111(1):57\u201369. https:\/\/doi.org\/10.1097\/00005537-200101000-00011","journal-title":"Laryngoscope"},{"issue":"10","key":"8430_CR11","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/lary.30021","volume":"132","author":"R Ruiz","year":"2022","unstructured":"Ruiz R, Balamuth N, Javia LR, Zur KB (2022) Systemic bevacizumab treatment for recurrent respiratory papillomatosis: long-term follow-up. Laryngoscope 132(10):2071\u20132075. https:\/\/doi.org\/10.1002\/lary.30021","journal-title":"Laryngoscope"},{"issue":"9","key":"8430_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136324","volume":"10","author":"F Ahmadizar","year":"2015","unstructured":"Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-vanderZee AH (2015) Efficacy and safety assessment of the addition of bevacizumab to adjuvant therapy agents in cancer patients: a systematic review and meta-analysis of randomized controlled trials [published correction appears in PLoS One. 2015;10(10):e0141704]. PLoS ONE 10(9):e0136324. https:\/\/doi.org\/10.1371\/journal.pone.0136324","journal-title":"PLoS ONE"},{"issue":"5","key":"8430_CR13","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.21873\/anticanres.16369","volume":"43","author":"S Fukuda","year":"2023","unstructured":"Fukuda S, Niisato Y, Tsuji M et al (2023) Relationship between safety and cumulative bevacizumab dose in patients with metastatic colorectal cancer who received long-term bevacizumab treatment. Anticancer Res 43(5):2085\u20132090. https:\/\/doi.org\/10.21873\/anticanres.16369","journal-title":"Anticancer Res"},{"issue":"1","key":"8430_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/lary.30180","volume":"133","author":"CS Derkay","year":"2023","unstructured":"Derkay CS, Wikner EE, Pransky S et al (2023) Systemic use of bevacizumab for recurrent respiratory papillomatosis: who, what, where, when, and why? Laryngoscope 133(1):2\u20133. https:\/\/doi.org\/10.1002\/lary.30180","journal-title":"Laryngoscope"},{"issue":"1","key":"8430_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/children10010054","volume":"10","author":"L Torres-Canchala","year":"2022","unstructured":"Torres-Canchala L, Cleves-Luna D, Arias-Valderrama O et al (2022) Systemic bevacizumab for recurrent respiratory papillomatosis: a scoping review from 2009 to 2022. Children (Basel) 10(1):54. https:\/\/doi.org\/10.3390\/children10010054","journal-title":"Children (Basel)"},{"issue":"10","key":"8430_CR16","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/lary.26662","volume":"127","author":"SR Best","year":"2017","unstructured":"Best SR, Mohr M, Zur KB (2017) Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey. Laryngoscope 127(10):2225\u20132229. https:\/\/doi.org\/10.1002\/lary.26662","journal-title":"Laryngoscope"},{"issue":"9","key":"8430_CR17","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1007\/s00405-022-07388-6","volume":"279","author":"L Pogoda","year":"2022","unstructured":"Pogoda L, Ziylan F, Smeeing DPJ, Dikkers FG, Rinkel RNPM (2022) Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review. Eur Arch Otorhinolaryngol 279(9):4229\u20134240. https:\/\/doi.org\/10.1007\/s00405-022-07388-6","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"8430_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2019.109762","volume":"129","author":"C Gates","year":"2020","unstructured":"Gates C, Tomboc P, Allison A, Carr M (2020) Bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in an infant. Int J Pediatr Otorhinolaryngol 129:109762. https:\/\/doi.org\/10.1016\/j.ijporl.2019.109762","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"5","key":"8430_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1001\/jamaoto.2013.1810","volume":"139","author":"DJ Rogers","year":"2013","unstructured":"Rogers DJ, Ojha S, Maurer R, Hartnick CJ (2013) Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg 139(5):496\u2013501. https:\/\/doi.org\/10.1001\/jamaoto.2013.1810","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"12","key":"8430_CR20","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/lary.30042","volume":"132","author":"K Hock","year":"2022","unstructured":"Hock K, Kennedy A, Howell R, Friedman A, de Alarcon A, Khosla S (2022) Surgery and adjuvant therapy improve derkay scores in adult and pediatric respiratory papillomatosis. Laryngoscope 132(12):2420\u20132426. https:\/\/doi.org\/10.1002\/lary.30042","journal-title":"Laryngoscope"},{"issue":"7","key":"8430_CR21","doi-asserted-by":"publisher","first-page":"E2277","DOI":"10.1002\/lary.29376","volume":"131","author":"Q Yang","year":"2021","unstructured":"Yang Q, Li Y, Ma L et al (2021) Long-term outcomes of juvenile onset recurrent respiratory papillomatosis with pulmonary involvement. Laryngoscope 131(7):E2277\u2013E2283. https:\/\/doi.org\/10.1002\/lary.29376","journal-title":"Laryngoscope"},{"issue":"10","key":"8430_CR22","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1002\/lary.30617","volume":"133","author":"SA Ballestas","year":"2023","unstructured":"Ballestas SA, Hidalgo Lopez J, Klein AM et al (2023) Long-term follow-up of parenteral bevacizumab in patients with recurrent respiratory papillomatosis. Laryngoscope 133(10):2725\u20132733. https:\/\/doi.org\/10.1002\/lary.30617","journal-title":"Laryngoscope"},{"key":"8430_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijporl.2017.10.034","volume":"104","author":"D Lu","year":"2018","unstructured":"Lu D, Huang M, Li Z et al (2018) Adaptation and validation of Mandarin Chinese version of the pediatric Voice Handicap Index (pVHI). Int J Pediatr Otorhinolaryngol 104:19\u201324. https:\/\/doi.org\/10.1016\/j.ijporl.2017.10.034","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"2","key":"8430_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK (2019) Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30(2):187\u2013200. https:\/\/doi.org\/10.1681\/ASN.2018080853","journal-title":"J Am Soc Nephrol"},{"key":"8430_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","volume":"182","author":"M Li","year":"2018","unstructured":"Li M, Kroetz DL (2018) Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther 182:152\u2013160. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.08.012","journal-title":"Pharmacol Ther"},{"issue":"2","key":"8430_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49(2):186\u2013193. https:\/\/doi.org\/10.1053\/j.ajkd.2006.11.039","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"8430_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jnci\/djq091","volume":"102","author":"ML Maitland","year":"2010","unstructured":"Maitland ML, Bakris GL, Black HR et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102(9):596\u2013604. https:\/\/doi.org\/10.1093\/jnci\/djq091","journal-title":"J Natl Cancer Inst"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-023-08430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-023-08430-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-023-08430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:07:20Z","timestamp":1710504440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-023-08430-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["8430"],"URL":"https:\/\/doi.org\/10.1007\/s00405-023-08430-x","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}